The Butantan Institute: History and Future Perspectives

Franco, Marcelo De; Kalil, Jorge

doi:10.1371/journal.pntd.0002862

Cited by 16 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Main Institutions Journals and Collaboration Networkmentioning

confidence: 99%

“…The Butantan Institute, a leader in contributing to studies in Brazil, is an institution that was born in 1901 in the state of São Paulo with to produce serum against bubonic plague [57]. Over the years, the institute has become one of the main scientific institutions in Brazil, known worldwide for studying the toxins of venomous animals, in addition to projects related to vaccines production, which attracted the attention of several international institutions for establishment of partnerships [57]. In relation to snakes, from the research carried out by the institution, various serums are produced, such as antibotropic, anticrotalic and antielapidic, which are made available to the population free of charge through the Health Ministry (see the Institute's website).…”

Section: Main Institutions Journals and Collaboration Networkmentioning

confidence: 99%

See 1 more Smart Citation

Studies about Snake Peptides: a Review about Brazilian Contribution

Assis

Bittar

Amorim

et al. 2022

Braz. arch. biol. technol.

View full text Add to dashboard Cite

The peptides present in snake venoms are studied because of their properties, constitutions, mechanisms of action and pharmacological potential. Recognizing this potential, the present study reports the contributions of Brazilian researchers about snake peptides, between 1975 and July 2020. Thus, this study serves as a basis for monitoring this theme in Brazil, referring to the trends and patterns of scientific production. The results indicated a significant increase in Brazilian scientific production over the years, highlighting institutions located in São Paulo state as, the Butantan Institute and University of São Paulo. The main journal where Brazilian authors publish their research is the Toxicon Journal. Collaborative networks were identified between Brazilian institutions and among other countries with Brazil. The most investigated species are found in brazilian territory, mainly those belonging to the genus Bothrops and the species Crotalus durissus. The increase in studies about this theme in Brazil is evident, however, a gap is highlighted for states outside the southeastern region and for other venomous species.

show abstract

Section: Main Institutions Journals and Collaboration Networkmentioning

confidence: 99%

Section: Main Institutions Journals and Collaboration Networkmentioning

confidence: 99%

Studies about Snake Peptides: a Review about Brazilian Contribution

Assis

Bittar

Amorim

et al. 2022

Braz. arch. biol. technol.

View full text Add to dashboard Cite

show abstract

“…Envenoming by C. d. terrificus caused neurotoxicity and less severe local effects, while B. jararaca envenoming caused local effects without neurotoxicity. At the Butantan Institute, Vital Brazil produced anti-bothroptic and anti-crotalic monovalent antisera, as well as antisera against a mixture of both venoms (first polyvalent antivenom), in mules and horses [19,24,25]. He subsequently introduced a successful program for distributing antivenoms across Brazil by setting up an antivenom-for-snakes exchange program, in which the farmers can exchange snakes for antivenom [24,26].…”

Section: Early and Current Antivenomsmentioning

confidence: 99%

Current research into snake antivenoms, their mechanisms of action and applications

Silva

2020

Biochemical Society Transactions

View full text Add to dashboard Cite

Snakebite is a major public health issue in the rural tropics. Antivenom is the only specific treatment currently available. We review the history, mechanism of action and current developments in snake antivenoms. In the late nineteenth century, snake antivenoms were first developed by raising hyperimmune serum in animals, such as horses, against snake venoms. Hyperimmune serum was then purified to produce whole immunoglobulin G (IgG) antivenoms. IgG was then fractionated to produce F(ab) and F(ab′)2 antivenoms to reduce adverse reactions and increase efficacy. Current commercial antivenoms are polyclonal mixtures of antibodies or their fractions raised against all toxin antigens in a venom(s), irrespective of clinical importance. Over the last few decades there have been small incremental improvements in antivenoms, to make them safer and more effective. A number of recent developments in biotechnology and toxinology have contributed to this. Proteomics and transcriptomics have been applied to venom toxin composition (venomics), improving our understanding of medically important toxins. In addition, it has become possible to identify toxins that contain epitopes recognized by antivenom molecules (antivenomics). Integration of the toxinological profile of a venom and its composition to identify medically relevant toxins improved this. Furthermore, camelid, humanized and fully human monoclonal antibodies and their fractions, as well as enzyme inhibitors have been experimentally developed against venom toxins. Translation of such technology into commercial antivenoms requires overcoming the high costs, limited knowledge of venom and antivenom pharmacology, and lack of reliable animal models. Addressing such should be the focus of antivenom research.

show abstract

“…Butantan Institute received the certificate of current good manufacturing practices (cGMP) from the Brazilian Regulatory Agency (ANVISA) and delivered the first lot of egg-based seasonal trivalent split influenza vaccine entirely produced in Brazil for the 2013 campaign. This was the first successful technological transfer completed in Brazil between Sanofi-Pasteur and the Butantan Institute [27][28]. For the 2019 vaccination campaign, Butantan Institute produced and delivered 59 million doses of trivalent seasonal influenza for the Brazilian Ministry of Health, representing 92% of the total demand (64 million doses), with the remaining doses supplied by Sanofi-Pasteur (Fig 1).…”

Section: Introductionmentioning

confidence: 99%

Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil

et al. 2020

View full text Add to dashboard Cite

Increasing pandemic influenza vaccine manufacturing capacity is considered strategic by WHO. Adjuvant use is key in this strategy in order to spare the vaccine doses and by increasing immune protection. We describe here the production and stability studies of a squalene based oil-in-water emulsion, adjuvant IB160, and the immune response of the H7N9 vaccine combined with IB160. To qualify the production of IB160 we produced 10 consistency lots of IB160 and the average results were: pH 6.4±0.05; squalene 48.8±.0.03 mg/ ml; osmolality 47.6±6.9 mmol/kg; Z-average 157±2 nm, with polydispersity index (PDI) of 0.085±0.024 and endotoxin levels <0.5 EU/mL. The emulsion particle size was stable for at least six months at 25˚C and 24 months at 4-8˚C. Two doses of H7N9 vaccine formulated at 7.5 μg/dose or 15 μg/dose with adjuvant IB160 showed a significant increase of hemagglutination inhibition (HAI) titers in sera of immunized BALB/c mice when compared to control sera from animals immunized with the H7N9 antigens without adjuvant. Thus the antigensparing capacity of IB160 can potentially increase the production of the H7N9 pandemic vaccine and represents an important achievement for preparedness against pandemic influenza and a successful North (IDRI) to South (Butantan Institute) technology transfer for the production of the adjuvant emulsion IB160.

show abstract

The Butantan Institute: History and Future Perspectives

Cited by 16 publications

References 24 publications

Studies about Snake Peptides: a Review about Brazilian Contribution

Studies about Snake Peptides: a Review about Brazilian Contribution

Current research into snake antivenoms, their mechanisms of action and applications

Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil

Contact Info

Product

Resources

About